Cognate Insights

[null]

Media Inquiries

Cognate’s team is available to discuss our recent news further.

Contact

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

MEMPHIS, Tenn., January 21, 2019 /PRNewswire/ — Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated... Read More

Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

Providing large scale manufacturing capacity for AZD1222 KEELE, United Kingdom, June 16, 2020 /PRNewswire/ — Cobra Biologics (Cobra), part of the Cognate BioServices family,... Read More

Cell & Gene Therapy Congress

December 1-4, 2020 in Amsterdam Read More

Biomanufacturing World Summit

November 16-17, 2020 in San Diego, California Read More

ESGCT 28th Annual Meeting

October 20th-23rd, 2020 Edinburgh, UK Read More

Join Cognate BioServices at the CAR-TCR Summit in Boston

September 14-17, 2020 Boston, MA Read More

Phacilitate Leaders Europe Forum

September 29th-30th, 2020 London, UK Read More

Meeting on the Mesa

October 14-16, 2020 in Carlsbad, California Read More

Cognate BioServices announces acquisition of Cobra Biologics

Cognate BioServices announces acquisition of Cobra Biologics Transformative acquisition creates global cell and gene therapy manufacturing services platform for both... Read More

Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry

Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry ... Read More
No More Posts